Kindred Biosciences (KIN) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Kindred Biosciences Announces Fourth Quarter and Year-End 2016 Financial Results
March 1, 2017 4:01 PM ESTSAN FRANCISCO, March 1, 2017 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN) (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2016. Â
"We are very pleased with the progress of Mirataz and Zimeta, including the recently announced approval of the efficacy technical section for Mirataz," stated Richard Chin, M.D., President and CEO of KindredBio. "We are looking forward to the transition to a... More
